Long Acting Injectable Cabotegravir for HIV Prevention

Publish date:

June 17, 2024

AETC Source

This presentation provides information on the current evidence supporting the use of long acting injectable cabotegravir (CAB-LA) for HIV prevention, indication, safety, efficacy, as well as advantages and disadvantages of CAB-LA.

Preview and Download

pptx

Preview

Download

Long Acting Injectable Cabotegravir for HIV Prevention

Browse more

Topic(s)

Treatment Monitoring and Support,

Drug Interactions & Adverse Effects,

HIV Life Cycle,

HIV Prevention,

Pre-exposure Prophylaxis

Type

Guideline Slides

Bimonthly Survey

Approximately what percentage of your patient visits are currently telehealth (phone or video) visits?

What is your primary profession/discipline

Other Non-Clinical Professional

Other Allied Professional

What is your primary functional role?

Specify Other Role

In what state or territory is your primary worksite?

To what extent have the resources and trainings available through this website increased your knowledge and skills to provide care for people with HIV?